title: FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
authors.affiliation: From the Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
authors.forename: Edward
authors.initials: E
authors.lastname: Cox
authors.forename: Katherine
authors.initials: K
authors.lastname: Laessig
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D064687:Diarylquinolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D064687:Diarylquinolines; C493870:bedaquiline